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The vasodilator phenoxybenzamine has been reported toassist in balancing the pulmonary and systemic circu-lations, thereby improving systemic oxygen deliveryafter the Norwood procedure.1 For this reason phenoxy-
benzamine is part of our routine postoperative management strat-
egy for infants undergoing the Norwood procedure. One potential
problem with phenoxybenzamine, however, is prolonged vasodi-
lation related to irreversible blockade of the -adrenergic recep-
tor.2 We have observed occasional profound hypotension associ-
ated with peripheral vasodilation that is refractory to standard
vasopressor therapy. Vasopressin is an alternative vasoconstricting
agent that does not act through the -adrenergic receptor and has
a relatively short half-life.3 We report its use as an effective
treatment for severe hypotension in an infant receiving phenoxy-
benzamine after a Norwood procedure.
Clinical Summary
On day 8 after birth, a 3.5-kg male infant with hypoplastic left
heart syndrome underwent the Norwood procedure. Phenoxyben-
zamine (GlaxoSmithKline, Mississauga, Ontario) at 0.25 mg/kg
was given at the start of cardiopulmonary bypass. Hypothermic
regional perfusion was used for cerebral protection during aortic
arch reconstruction. An oximetric catheter was placed directly in
the superior vena cava for continuous monitoring of systemic
venous oxygen saturation. The sternum was stented open accord-
ing to our standard protocol, and the skin was closed.
Initial postoperative management included milrinone at 0.66
g/(kg  min), dopamine 7.5 g/(kg  min), and sodium nitroprus-
side 3 g/(kg  min). A phenoxybenzamine infusion (1 mg/[kg  d])
was started 6 hours after the operation. Phenoxybenzamine was
discontinued 23 hours after the operation, and a norepinephrine
infusion was started because of hypotension and anuria with clin-
ical and biochemical evidence of excellent systemic perfusion
(Figure 1). Blood pressure did not improve with norepinephrine
infusion, and the infant became more tachycardic (average heart
rate increased from 169 to 175 beats/min). Vasopressin (Pharma-
ceutical Partners of Canada Inc, Toronto, Ontario) at 0.0003 to
0.0006 U/(kg  min) was started 31 hours after the operation for
refractory hypotension and persistent anuria despite norepineph-
rine infusion. Blood pressure improved, and spontaneous urinary
output resumed. Average heart rate decreased to 167 beats/min on
discontinuation of norepinephrine. The pulmonary/systemic blood
flow ratio (Q˙ /p) calculated by assuming a pulmonary venous
saturation of 96% was 0.85 prior to starting vasopressin therapy.
Q˙ /p had climbed to 1.8 before discontinuation of vasopressin
therapy 37 hours later. Delayed sternal closure was accomplished
on postoperative day 5, and the patient was discharged home 11
days later.
Discussion
Phenoxybenzamine reduces systemic vascular resistance, causing
hypotension by blocking smooth muscle cell -adrenergic recep-
tors. Because phenoxybenzamine covalently binds to the -adren-
ergic receptor, it leads to complete and irreversible blockade.
Norepinephrine and other -agonists therefore have impaired ef-
ficacy in the presence of phenoxybenzamine (Figure 2). Return of
sensitivity to catecholamines depends on synthesis of new recep-
tors and may take several days.2 Vasopressin has recently been
described as an alternative vasoconstricting agent for children with
vasodilatory shock after cardiac surgery.4 Vasopressin acts on the
V1 receptor of smooth muscle cells5 rather than the -adrenergic
receptor and is therefore expected to have preserved activity even
in the presence of phenoxybenzamine (Figure 2). In addition,
vasopressin has a relatively short half-life of 10 to 35 minutes.3
The infant we described here had severe hypotension that was
refractory to norepinephrine, presumably as a result of -blockade
by phenoxybenzamine. The institution of vasopressin therapy was
associated with rapidly improving blood pressure and return of
renal function. However, these beneficial effects occurred at the
expense of a predictable increase in Q˙ /p. The rising Q˙ /p was most
likely related to systemic vascular resistance elevation, but it may
have been further influenced by the pulmonary vasodilation that
may occur with low-dose vasopressin.3 Despite the negative im-
pact of vasopressin on Q˙ /p and the arterial-venous oxygen satura-
tion difference, this patient did not show clinical evidence of
impaired cardiac output and did not have lactic acidosis (Figure 1).
In contrast to norepinephrine, which stimulates cardiac -adrenergic
receptors, vasopressin was not associated with increased heart rate
and therefore may have had less impact on myocardial oxygen con-
sumption. A syndrome of inappropriate antidiuretic hormone as a
result of exogenous vasopressin administration did not occur in this
infant. A paradoxic improvement in urinary output, as seen in this
case (Figure 1), does occur in certain vasodilatory states.3
Any potential benefit of vasopressin therapy must be balanced
against possible adverse effects, including complications of severe
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vasoconstriction or enhanced platelet aggregation that can occur at
higher dosage.3 Although this experience represents only a single
case, an understanding of the pharmacology of phenoxybenzamine
suggests that vasopressin could be useful to modulate its effect,
allowing more precise control of systemic vascular resistance and
Q˙ /p. Further prospective investigation is necessary for definitive
identification of the risks and benefits of this strategy.
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Figure 1. Line graph depicting mean arterial pressure in millimeters of mercury (open squares, numbers on axis to
left), arterial-venous oxygen saturation difference as a percentage (open diamonds, numbers on axis to left),
urinary output in milliliters per kilogram per minute (filled circles, numbers on axis to right), and serum lactate in
millimoles per liter (filled triangles, numbers on axis to right) during early post operative period. Dose and timing
for norepinephrine and vasopressin infusion are indicated above graph (bold lines). Hatched area represents
duration of vasopressin infusion.
Figure 2. Diagrammatic representation of -adrenergic receptor
() blockade by phenoxybenzamine. Because phenoxybenzamine
is covalently bound to -adrenergic receptor, action of norepi-
nephrine is blocked, phospholipase C (PLC) is not activated, and
downstream signaling events required for smooth muscle cell
contraction do not occur. In contrast, interaction of vasopressin
with its receptor (V1) is not inhibited by phenoxybenzamine.
Phospholipase C is activated and generates inositol triphosphate
(IP3), which causes intracellular calcium (Ca
) release and
vascular smooth muscle cell contraction.
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